profiles from all known Campylobacter species. Similarity between the normalised fingerprints was determined by the Pearson product moment correlation coefficient and a UPGMA dendrogram was constructed. The profiles from both isolates clearly formed a cluster together with C. coli reference strains (Fig. 1) .
Using LOS gene cluster-specific PCR tests, the 664H2004 strain was demonstrated to harbour a B-type gene cluster [7] . For GB50, neither the cst2 nor the cgtA gene was shown to be present. This convincingly demonstrates that this strain does not harbour the neuropathy-associated LOS gene cluster types A, B or C. Using primers based on the C. coli RM2228 LOS gene cluster, we amplified the LOS locus of GB50, but we could not amplify the LOS locus of 664H2004. Complete sequencing of the novel GB50 LOS gene cluster revealed 12 open reading frames (ORFs) that included five putative glycosyltransferases and a few ORFs seemingly unrelated to LOS biosynthesis ( Table 1) .
The LOS of C. coli strain GB50 did not bind cholera toxin, hence, the presence of a GM1-like ganglioside mimic could be excluded. The acute phase pre-treatment serum from patient GB50 showed a high level of IgG activity to the LOS from the GB50 strain (Table 2 ). This activity was significantly higher than in the serum from ten healthy blood donors. In addition, in the serum from patient GB50, IgM activity was found for this LOS, although it was less than the IgG activity. Some of the healthy blood donors also showed this elevated level of IgM. Probing the LOS with six specific monoclonal anti-ganglioside antibodies (DG-1, DG-2, TBG-3, EG-7, EG-3 and EG-1) did not reveal any reactivity. These monoclonal antibodies were raised by immunisation with C. jejuni LOS and bound to various (combinations of) gangliosides (Table 2) . Interestingly, regular mass spectrometry analysis on O-deacylated C. coli LOS [1] did not reveal a structural overlap between this LOS and the previously determined C. jejuni LOS structures. It appeared that the GB50 LOS did not contain sialic acid based on MS/MS analysis. The LOS from the 664H2004 strain was shown to contain di-NeuAc based on MS/MS analysis.
The serum from patient GB50 was tested in a standardised enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to the gangliosides GM1, GM2, GD1a, GD1b, GD3 and GQ1b [8] . Serum was positive for IgG, IgM and IgA antibodies to the gangliosides GM1 and, to a lesser extent, to GD1b (Table 2 ). These gangliosides share the terminal Gal(β1-3)GalNac to which these antibodies are probably directed. Accordingly, the serum from this patient contained high IgG, IgM and IgA activity to the non-ganglioside glycolipid asialo-GM1, which has the same terminal disaccharide. Such a structure, however, was not identified in the LOS of the C. coli isolate from this patient. This suggests that this patient might have been coinfected with another organism expressing a GM1 mimic, possibly a C. jejuni strain, responsible for a non-GBSrelated induction of a cross-reactive antibody response to GM1. In inhibition ELISA experiments, anti-GM1 IgG activity in 1:400 dilutions of serum from GB50 was not reduced by LOS from this strain in concentrations of up to Fig. 1 Amplified fragment length polymorphism (AFLP) analysis of the two Campylobacter coli strains isolated from patients GB50 and 664H2004. Note that, despite their diverse geographic origins, these strains cluster, but clearly fall within the C. coli cluster 200 μg/ml, demonstrating that these antibodies do not crossreact with the LOS from the C. coli isolate from the patient. In control studies, this antibody activity was reduced to a level of less than 5% by pre-incubation with LOS from a C. jejuni isolate GB2 from another GBS patient, in which mimicry with GM1 was previously demonstrated by MS [9] .
Overall, we have comprehensively characterised two C. coli strains isolated from GBS patients with a variety of state of the art technologies. One strain (664H2004) harboured disialylated LOS, but, unfortunately, no serum was available to measure either anti-ganglioside or anti-LOS antibodies in the GBS patient herself. The other strain from the Dutch patient (GB50) had non-sialylated LOS, which showed no binding to cholera toxin or to monoclonals specific for several gangliosides. However, the serum from patient GB50 from which C. jejuni GB50 was isolated did contain antibodies to the LOS from this strain, indicating that this infection led to a specific immune response to C. coli strain GB50. The role of this immune response in the pathogenesis of GBS is currently unknown, although other examples of GBS patients infected with nonganglioside mimicking strains of C. jejuni have been described [10] . The serum from GB50, however, also contained antibodies to GM1 and GD1a, which do not n.a.; not available 1 Monoclonal antibodies DG-1 (to GM1), DG-2 (to GM1/GD1b/GA1), TBG-3 (to GD1a), EG-7 (to GD1b), EG-3 (to GQ1b) and EG-1 (to GT1a/ GQ1b) 2 Significantly higher than antibody activity to this LOS in serum from ten healthy blood donors 3 Serum IgG, IgM and IgA tested to GM1, GM2, GD1a, GD1b, GD3 and GQ1b 4 The cross-reactivity of 1:400 diluted serum anti-GM1 IgG antibodies from patient GB50 to LOS from C. coli GB50 and 664H2004 were determined by inhibition enzyme-linked immunosorbent assay (ELISA) cross-react with LOS from GB50, as expected, although they do cross-react with LOS from a C. jejuni with a known GM1 mimic. These serological findings in patient GB50 strongly suggest that this patient was infected with at least two micro-organisms, one of which induced the antiganglioside antibodies leading to GBS (possibly a C. jejuni strain), and C. coli, which also induced an immune response, but probably did not trigger GBS. In summary, we could not produce any evidence that molecular mimicry plays a role in the pathogenesis of GBS that is preceded by a C. coli infection. It is still not clear whether C. coli isolated from the faeces of GBS patients can play a role in the development of GBS. Additional GBS patients and their C. coli strains need to be reported and characterised in detail in order to better understand the pathogenesis of GBS in these patients.
